Table of Contents Table of Contents
Previous Page  640 / 1726 Next Page
Information
Show Menu
Previous Page 640 / 1726 Next Page
Page Background

Stage I ‘medium risk ‘ (n=527)

VBT

EBRT+VBT

Vaginal recurrence

(crude)

2.7%

1.9%

Locoregional

5.0%

1.5%

Overall Survival

90%

89%

Toxicity Gr 3: GI

0%

2%

vagina 0.8%

0%

Similar QoL results favoring VBT alone

Sorbe et al, IJROBP 2012 + Int J Gynecol Cancer 2012

Swedish randomised trial (1997-2008)